Watch Vaso Corp for free: we tell you when fair value or trend changes.

Vaso Corp (VASO) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Vaso Corp stock $0.27, price $0.29, that is 6.9% below the price, quality 63 out of 100. Rating: fairly valued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.

24 models, one by oneBear $0.2700 to bull $0.2800 Growth analysisrevenue history, year by year Quality 63/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

Thin data Nov 7, 2026

Vaso Corp

VASO · US

Fairly valued, in an uptrend

The stock costs about what our calculation considers fair.

Quality 63/100

Low debt

Generates free cash flow

Ranks above peers (11/13)

Fair value $0.2700 · Fairly valued

Mixed Growth (revenue 5y +5.0 %/yr in USD)

Thin margins · 2.8% net margin (TTM) · excl. goodwill write-downs +8.0%

Profit last quarter 48% below a year ago.

Narrow moat 35/100 · thin data

Thin data

Watch Vaso Corp for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.

How to read this chart

60‑month range $0.0420 – $0.3545 · fair‑value band $0.2700 – $0.2800 · the $0.2900 price screens above the $0.2700 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 7, 2026.

Follow Vaso in your weekly email

Every Wednesday you see whether Vaso is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Vaso Corporation, together with its subsidiaries, operates in the healthcare equipment and information technology industries in the United States and internationally. It operates in three segments: IT, Professional Sales Service, and Equipment.

Show moreShow less

The IT segment primarily focuses on healthcare IT and managed network technology services. This segment offers managed network infrastructure, such as routers, switches, and other core equipment; managed network transport; and managed network security services.

The Professional Sales Service segment principally focuses on the sale of healthcare capital equipment for General Electric Healthcare, Inc. (GEHC) into the health provider middle market.

Its offerings include GEHC diagnostic imaging equipment and ultrasound systems, GEHC service agreements, GEHC training, and GEHC and third-party financial services. The Equipment segment primarily focuses on the design, manufacture, sale, and service of proprietary medical devices and software.

This segment offers Biox series Holter monitors and ambulatory blood pressure recorders; ARCS series analysis, reporting, and communication software for ECG and blood pressure signals, including cloud-based software and algorithm subscription services; MobiCare multi-parameter wireless vital-sign monitoring systems; and Enhanced External Counterpulsation therapy systems for non-invasive and outpatient treatment of ischemic heart disease.

The company was formerly known as Vasomedical, Inc. and changed its name to Vaso Corporation in November 2016. Vaso Corporation was incorporated in 1987 and is headquartered in Plainview, New York.

Stock analysis

Vaso Corp (VASO) currently trades at $0.2900, while our model-based Fair Value estimate is $0.2700, so the stock looks roughly fairly valued today (gap 7.4%).

Valuation

Bull case: the Growth DCF group reads highest at a median of $0.7000 per share, and 10 of the 24 models we run sit above the $0.2900 price.

Bear case: the Asset-Based group reads lowest at $0.0600, and 14 of the 24 models stay below the price. Data coverage for this calculation is low.

Scenario range: $0.2700 (bear) to $0.2800 (bull), the price of $0.2900 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 63/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Vaso Corp reported revenue of $89.1M in FY2025 versus $75.6M in FY2021, a compound +4.2%/yr. Reported net income was $1.6M in FY2025, compounding −28.8%/yr from FY2021.

Key figures

Market cap $51.0M Micro · P/E ratio 14.5 · P/S ratio 0.57 · EPS (TTM) $0.0200 · Net margin 2.8% · Return on equity 6.6% · Return on assets (EBIT) 5.2% (5-year average) · Operating margin 8.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 35 out of 100 (low confidence).

What moves the price

The share trades about 6% below its 52-week high and 164% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 3% fair-value upside, at −7%, VASO screens richer than that median.

Fair Value models

Bear $0.2700 Fair Value $0.2700 Bull $0.2800

Price $0.2900 · Downside -6.9%

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($0.0172 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Best data coverage

FCF DCF $0.6500 $0.9100 $1.29 81

Growth DCF $0.6500 $0.8800 $1.18 79

Owner Earnings $0.3500 $0.4300 $0.5600 78

All 24 models by family

DCF Models

FCF DCF $0.6500 $0.9100 $1.29 81

Owner Earnings $0.3500 $0.4300 $0.5600 78

5Y Revenue Exit $0.4300 $0.5200 $0.6200 74

5Y EBITDA Exit $0.4600 $0.5800 $0.7200 77

5Y P/E Exit $0.4600 $0.5700 $0.6900 72

10Y Revenue Exit $0.5200 $0.6200 $0.7500 68

10Y EBITDA Exit $0.5400 $0.6600 $0.8200 70

10Y P/E Exit $0.5300 $0.6500 $0.8000 65

Earnings-Based

Graham-Dodd $0.0600 $0.2600 $0.3600 64

Lynch FV $0.0700 $0.1000 $0.1300 61

PEG = 1.0 $0.0700 $0.1000 $0.1300 57

EPV $0.2700 $0.2700 $0.2800 74

Multiples

P/E Multiple $0.1500 $0.2000 $0.2500 63

P/S Multiple $0.1100 $0.1500 $0.1900 58

P/B Multiple $0.1200 $0.1600 $0.2000 55

EV/EBIT $0.1800 $0.2300 $0.2700 66

EV/EBITDA $0.2100 $0.2600 $0.3200 67

EV/Revenue $0.1500 $0.1900 $0.2200 54

Asset-Based

NCAV (Graham) $0.0500 $0.0600 $0.0900 54

Growth DCF

Growth DCF $0.6500 $0.8800 $1.18 79

Rev-Margin DCF $0.4300 $0.5200 $0.6400 74

Economic Profit

Residual Income $0.1200 $0.1200 $0.1200 71

ROIC Compounder $0.2700 $0.2700 $0.2800 72

Growth Earnings

Growth-Adj P/E $0.1200 $0.1700 $0.2200 68

Open the full fair value analysis →

Quality Score breakdown

Overall quality 63/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 50

How much profit the company makes from its sales and capital

Quality Growth 40

Are margins and returns getting better?

Cashflow 71

Do the profits arrive as real cash?

Financial strength 71

Debt, balance sheet and risk of trouble

Investment 74

Does it invest with discipline instead of growing at any price?

Low Volatility 40

How calm the share price moves, does not count

Price momentum 88

Price momentum of the last 3 to 12 months, does not count

Near the 52-week high 95

Distance to the 52-week high, does not count

New shares 80

Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 61/100

Revenue is growing, but margins or cash flow do not fully confirm the trend.

Revenue growth 1 year

+2.7%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+3.6%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+5.0%

Start year 2020 (pandemic). Over 10 years: +4.6% a year

Revenue growth 36 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+20.8%

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.

+59.2%

Earnings growth per share plus dividend.

Earnings per share, growth per year+59.2%

Dividend (yield on the price)0.0%

Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.33.6% vs 2.1%, picking up

Pace: the 5-year rate starts in 2020 (pandemic)

Growth Forecast

Little optimism in the price

The price assumes less growth than the company has delivered so far.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

−17.6%

The company could shrink this much every year for the next five years and today's price would still be justified.

What forecasts expect

n/a

No analyst forecast available.

After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −19.5% a year for the price.

Watch VASO, get fair value alerts →

Compare Vaso Corp with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 117 stocks

Beats the industry median on 10/12 measures

Overall it ranks above its industry peers.

Valuation

Quality Score 63 · Above median

Fair Value upside −6.9% · Above median

Profitability

Return on equity (12 months) 6.6% · Above median

Return on assets 1.8% · Above median

Net margin (12 months) 2.8% · Below median

Operating margin (12 months) 8.7% · Above median

Growth and dividend

Revenue growth (quarter YoY) 8.3% · Below median

Valuation Multiplesvs Health Information Services median · lower = cheaper

P/E (12 months) 14.5× · Cheapest 25%

P/B 1.73× · Cheaper than median

P/S (12 months) 0.57× · Cheapest 25%

Price / free cash flow (fiscal year) 6.1× · Cheapest 25%

EV/EBITDA 5.1× · Cheapest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)24 · sector 5

FUTURE (revenue growth)42 · sector 46

PAST (return on equity)26 · sector 10

HEALTH (low debt)100 · sector 98

DIVIDEND (yield)0 · sector 41

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value	Compare
Veeva Systems Inc VEEV	$303.73	$334.10	+10%	vs VASO
HealthEquity, Inc HQY	$103.63	$113.99	+10%	vs VASO
Doximity, Inc DOCS	$32.51	$35.76	+10%	vs VASO
Inventurus Knowledge Solutions Limited IKS	₹1,657	₹1,823	+10%	vs VASO
Waystar Holding WAY	$28.35	$29.10	+3%	vs VASO
Hinge Health, Inc HNGE	$115.76	$51.25	−56%	vs VASO
Pro Medicus Limited PME	A$205.49	A$85.12	−59%	vs VASO
BrightSpring Health Services, Inc BTSG	$67.15	$25.72	−62%	vs VASO
XtalPi Holdings 2228	HK$6.13	HK$1.53	−75%	vs VASO
Privia Health Group PRVA	$24.42	$5.52	−77%	vs VASO

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks Undervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator

Run the numbers yourself: free valuation calculators

DCF Calculator P/E Ratio Calculator PEG Ratio Calculator Graham Number Peter Lynch Formula DDM Calculator Intrinsic Value Intrinsic vs Extrinsic Value P/E Ratio by Sector

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Vaso Corp: fair value per Fair Value Calculator

<a href="https://www.fairvalue-calculator.com/stock/VASO?utm_source=embed&amp;utm_medium=badge" target="_blank" rel="nofollow noopener"><img src="https://www.fairvalue-calculator.com/embed/VASO.US.svg" width="360" height="84" alt="Vaso Corp: fair value per Fair Value Calculator" style="border:0;max-width:100%" loading="lazy"></a>

Cite: Fair Value Calculator (2026). "Vaso Corp Fair Value". https://www.fairvalue-calculator.com/stock/VASO

Frequently asked questions

Is Vaso Corp (VASO) overvalued or undervalued?

As of Nov 7, 2026, our model estimates a fair value of $0.2700 versus a price of $0.2900, about 7% lower (fairly valued).

What is the fair value of VASO?

Our model-based fair value for Vaso Corp is $0.2700 (as of Nov 7, 2026), built from audited fundamentals. The current price: $0.2900.

What is the quality score of VASO?

Vaso Corp has a Quality Score of 63/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Vaso Corp (VASO)?

Our model-based price target is the fair value of $0.2700 (as of Nov 7, 2026) from 24 valuation models. Cautious scenario $0.2700, optimistic scenario $0.2800. It is a calculation from audited fundamentals, not an analyst target.

What is the Vaso Corp stock forecast for 2026?

Our models put fair value at $0.2700, about 7% lower versus a price of $0.2900 (fairly valued). Cautious scenario $0.2700, optimistic scenario $0.2800. The calculation is refreshed regularly with new filings.

What is the revenue of Vaso Corp (VASO)?

Vaso Corp reported trailing-twelve-month revenue of about $89.6M (latest available figure, as of Nov 7, 2026).

What growth is priced into Vaso Corp (VASO)?

For today's price to be fair in a discounted-cash-flow model, Vaso Corp would have to grow free cash flow by -17.6 % per year for five years (discount rate 12.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +5.0 % per year. As of Nov 7, 2026.

What discount rate (WACC) does the fair value of VASO use?

Our models discount Vaso Corp at 12.0 %: a base by market capitalisation (micro), damped by beta 0.76, country premium for USA. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Vaso Corp that is -17.6 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.0 %) and the same formula as our fair value.

How much growth has Vaso Corp (VASO) delivered so far?

Over the past 5 years revenue at Vaso Corp grew +5.0 % a year. The price currently implies free-cash-flow growth of -17.6 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of Vaso Corp (VASO) growing?

The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Vaso Corp (-17.6 % per year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of Vaso Corp (VASO)?

The free-cash-flow yield on the price is 16.36 %: that much free cash flow Vaso Corp produces per unit of market value. When it exceeds the discount rate of our models (12.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of Vaso Corp (VASO)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Vaso Corp it is $0.2700 per share (as of Nov 7, 2026), against a price of $0.2900. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).

Is Vaso Corp stock overvalued or undervalued in 2026?

As of Nov 7, 2026, VASO trades above its calculated fair value: price $0.2900, fair value $0.2700, a gap of about −7% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of VASO?

No. The price is what the market pays today ($0.2900); the fair value is what the company's own numbers justify ($0.2700). For Vaso Corp the two are $0.0200 per share apart. That gap is exactly why we show both numbers side by side.

How much is Vaso Corp worth?

The market values Vaso Corp at about $51.0M (market capitalisation, as of Nov 7, 2026). Per share that is $0.2900; our models calculate a fair value of $0.2700 per share.

What do the bullish and bearish scenarios say about VASO?

Our models span a range for Vaso Corp: cautious scenario $0.2700, base $0.2700, optimistic $0.2800 per share (as of Nov 7, 2026, price $0.2900). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of VASO?

Vaso Corp trades at a price-to-earnings ratio of 14.5 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $0.2700 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 14.5 (reported for FY2025: 29.0). Median P/E at fiscal year-end, 8 fiscal years (2016 to 2025), reported earnings, FY2020, FY2025 ex one-offs: 16.6. Other multiples: P/B 1.7, P/S 0.6, EV/EBITDA 5.1.

How solid is the balance sheet of Vaso Corp (VASO)?

Balance-sheet figures for Vaso Corp (as of Nov 7, 2026): return on equity 6.6%. They feed the Quality Score of 63/100, which measures business quality independently of the share price.

How far is VASO from its 52-week high?

Vaso Corp trades at $0.2900, about 6% below its 52-week high of $0.3100 and 164% above the low of $0.1100 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $0.2700 is for.

Which stocks are comparable to Vaso Corp?

From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Vaso Corp stock attractive at the current price?

The data as of Nov 7, 2026: price $0.2900, calculated fair value $0.2700 (−7%), Quality Score 63/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of VASO calculated?

We run Vaso Corp through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $0.2700 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 13.3% above its aggregate fair value. Vaso Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Vaso Corp (VASO)?

The closing price on Nov 6, 2026 was $0.2900. Our model-based fair value is $0.2700, about 7% lower (fairly valued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Vaso Corp right now?

The price sits above even our optimistic bull case ($0.2800). The favourable scenario is already priced in. The price sits close to our fair value, market and models broadly agree here, little valuation tension. The models converge in a tight band ($0.2700 to $0.2800), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Vaso Corp

How large is the market capitalisation of Vaso Corp (VASO)?

The market capitalisation of Vaso Corp is $51.0M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Vaso Corp (VASO)?

The price-to-sales ratio of Vaso Corp is 0.57 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Vaso Corp (VASO)?

Earnings per share at Vaso Corp are $0.0200 (price ÷ EPS = P/E 14.5). Earnings per share over the last twelve months: total profit spread across every single share.

What is the net margin of Vaso Corp (VASO)?

The net margin of Vaso Corp is 2.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Vaso Corp (VASO)?

The return on equity (ROE) of Vaso Corp is 6.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Vaso Corp (VASO)?

On an EBIT basis the return on assets of Vaso Corp is 5.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Vaso Corp (VASO)?

The operating margin of Vaso Corp is 8.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Vaso Corp (VASO)?

Revenue at Vaso Corp is growing +8.3% versus a year earlier (3y avg +3.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Vaso Corp (VASO)?

Earnings per share at Vaso Corp are growing −47.5% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net cash does Vaso Corp (VASO) hold?

Vaso Corp holds more cash than debt, $10.0M net (fiscal year 2022). The company holds more cash than debt, a safety cushion.

Free · no account needed

Watch Vaso Corp in the live analysis

One click puts Vaso Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.